IP Library › Patent Application 15344756
Patent Application
App. No. 15/344,756

TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/344,756
Abstract

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: with X selected from C 4-8 cycloalkyl, C 4-8 cycloalkenyl, C 4-9 spirocycloalkyl, C 4-9 spirocycloalkenyl, C 4-8 oxacycloalkyl, C 4-8 dioxacycloalkyl, C 6-8 oxacycloalkenyl, C 6-8 dioxacycloalkenyl, C 6 cyclodialkenyl, C 6 oxacyclodialkenyl, C 6-9 oxaspirocycloalkyl and C 6-9 oxaspirocycloalkenyl ring, such that X is substituted with A, wherein A is —C 1-6 alkyl-halo. These compounds are useful for the treatment of HIV and AIDS.

Claims (10)

1 . A pharmaceutical composition which comprises the compound

together with one or more pharmaceutically acceptable carriers, excipients and/or diluents, and which comprises an additional AIDS treatment agent selected from the group consisting of: (a) an AIDS antiviral agent; (b) an anti-infective agent; (c) an immunomodulator; and (d) an HIV entry inhibitor.

2 . A pharmaceutical composition according to claim 1 wherein said additional AIDS treatment agent dolutegravir.

3 . A pharmaceutical composition according to claim 2 wherein said additional AIDS treatment agent is cabotegravir.

4 . A pharmaceutical composition according to claim 2 wherein said additional AIDS treatment agent is 3TC.

5 . A method for treating a mammal infected with the HIV virus comprising administering to said mammal the compound

and which comprises administration of an additional AIDS treatment agent selected from the group consisting of: (a) an AIDS antiviral agent; (b) an anti-infective agent; (c) an immunomodulator; and (d) an HIV entry inhibitor.

6 . The method of claim 4 wherein said additional AIDS treatment agent is dolutegravir.

7 . The method of claim 5 wherein said additional AIDS treatment agent is cabotegravir.

8 . The method of claim 5 wherein said additional AIDS treatment agent is 3TC.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2017
From: SIT, SING-YUEN; CHEN, YAN; CHEN, JIE; SWIDORSKI, JACOB; VENABLES, BRIAN LEE; SIN, NY; MEANWELL, NICHOLAS A.; REGUEIRO-REN, ALICIA; HARTZ, RICHARD A.; XU, LI; LIU, ZHENG
To: BRISTOL-MYERS SQUIBB COMPANY
Reel/Frame 043433/0433 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2017
From: BRISTOL-MYERS SQUIBB COMPANY
To: VIIV HEALTHCARE UK (NO.4) LIMITED
Reel/Frame 043433/0668 →